Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

AI Summary: TTLC 2026 brought together lung cancer experts to present symposia on advanced NSCLC topics — from RAS inhibition to mechanisms of EGFR resistance — and unveiled new clinical data. The meeting, including LungCancerRx LIVE Season 2 sessions, fostered debate, rapid data exchange and collaborations likely to steer upcoming trials and treatment approaches.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 2 months

Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 2 months

Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 3 months

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months

HORMAD1 emerges as a potential target in triple‑negative breast cancer / 2 months

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 2 months

Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months